Cardio-Oncology Summit 2025

Program Overview

The NewYork-Presbyterian Cardio-Oncology Summit program will provide a comprehensive overview of the latest developments in the rapidly emerging field of cardio-oncology. The program consists of 6 unique sessions that will address key questions in the management of cardiac disease in patients with cancer as well as cancer survivors. NewYork-Presbyterian's Cardio-Oncology program has established new clinical pathways for Cardio-Oncology care from prevention of cardiac disease, to the management of long-term cardiac toxicities. Sessions will consist of case based discussions, lectures and Q&A, presented by a multidisciplinary group of experts in the field of cardio-oncology from NewYork-Presbyterian, as well as invited guest faculty.

Learning Objectives

1. To identify cardiotoxicities associated with contemporary lung cancer therapies

2. To learn about recent advances in the treatment of immune checkpoint inhibitor myocarditis

3. To review current recommendations for management of advanced heart failure in patients with cancer

4. To understand the mechanism of 5 Flurouracil associated cardiotoxicity, risk factors and safety of re-challenging patients who develop cardiotoxicity.

5. To review contemporary diagnosis and management strategies of TTR and AL amyloidosis

6. To learn the current approach to identification and management of cardiac tumors

7. To review the latest guidelines regarding prevention and treatment of anthracycline and anti her 2 therapy related cardiotoxicity

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Columbia University. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians

Amedco LLC designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Amedco LLC designates this activity for a maximum of 6.75 ANCC contact hours.

Nurse Practitioners

The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.

Physician Assistants

The National Commission on Certification of Physician Assistants (NCCPA) states that AMA PRA Category 1 Credits are acceptable for continuing medical education requirements for recertification for PAs.

Amedco LLC designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.

Agenda

Friday, February 28

8:15 AM - 9:00 AM

Registration & Vendor Exhibits

9:00 AM - 9:05 AM

Welcome Remarks

James McKiernan, MD John K. Lattimer Professor of Urology CEO, of ColumbiaDoctors Interim Dean of Columbia University Vagelos College of Physicians and Surgeons

9:05 AM

Session 1: Cardio-Oncology Considerations in Lung Cancer

Moderator: Michelle Bloom, MD Panel: Brian Henick, MD, Jayant Raikhelkar, MD

9:05 AM - 9:15 AM

Case Presentation: A case of TKI Induced Cardiotoxicity in Lung Cancer Patients

Jaya Batra, MD

9:15 AM - 10:15 AM

Contemporary Treatment of Lung Cancer

Brian Henick, MD

9:30 AM - 9:45 AM

Cardiotoxicity of Lung Cancer Treatment

Jayant Raikhelkar, MD

9:45 AM - 10:05 AM

Panel Discussion

10:05 AM

Session 2: Treatment of ICI Myocarditis: What Tools Can We Use?

Moderator Dor Lotan, MD Panel: Adam Mor, MD, PhD, Jayant Raikhelkar, MD, Stephanie Feldman, MC, FACC, Andrea Valledor, MD

10:05 AM - 10:15 AM

Case Presentation: ICI Myocarditis

Andrea Valledor, MD

10:15 AM - 10:30 AM

Panel Discussion

10:30 AM - 10:45 AM

Case Presentation: ICI Myocarditis

10:45 AM - 11:05 AM

Panel Discussion

11:05 AM - 11:15 AM

Case Presentation: A Patient with Cardiogenic Shock with Neck Mass

11:05 AM - 11:05 PM

Session 3: Patient Selection for Advanced Therapies: Is Cancer an Absolute No?

Moderator: Nir Uriel, MD, MSc Panel: Michelle Bloom, MD, FACC, FHFSA, F-ICOS, Gabriel Sayer, MD, Farhana Latif, MD, Ilan Richter, MD, MPH, Elena Donald, MD

11:15 AM - 11:25 AM

Didactics

11:25 AM - 11:35 AM

Case Presentation: A Patient with Early Diagnosis of Cancer after Heart Transplantation

11:35 AM - 12:00 PM

Panel Discussion

12:00 PM - 1:00 PM

Lunch & Vendor Exhibits

1:00 PM - 1:10 PM

Case Presentation

Elissa Driggin, MD

1:10 PM - 1:30 PM

Keynote Lecture: The Enigma of 5 Fluorouracil Cardiotoxicity: Lessons Learned and Future Directions

Joseph Carver, MD, FACC, F-ICOS University of Pennsylvania

1:30 PM - 1:50 PM

Keynote Lecture Discussion

Panel: Yoanna Pumpalova, MD, Beatrice Dionigi, MD, Anne Goldberg, NP

1:50 PM

Session 4: Clinical Questions in Cardiac Amyloidosis

Moderator: Mathew Maurer, MD Panel:

1:50 PM - 2:10 PM

Putting the Algorithm to Work: Case-Based Application of the Cardiac Amyloidosis Diagnostic Pathway

2:10 PM - 2:30 PM

Targeting Transthyretin A New Era in ATTR Cardiac Amyloidosis

2:30 PM - 2:50 PM

The Challenging Landscape of AL Amyloidosis: Navigating the Path to Transplant

2:50 PM - 3:05 PM

Break & Vendor Exhibits

3:05 PM

Session 5: Cardiac Tumors

4:00 PM

Session 6: ESC Guidelines with a Focus on Anthracycline and Anti HER2 Therapies

Moderator: Stephanie Feldman, MD, FACC

4:00 PM - 4:10 PM

Case Presentation: Anthacycline Induced Cardiotoxicity

Suely Roman, MD

4:10 PM - 4:25 PM

Panel Discussion

4:25 PM - 4:40 PM

Case Presentation: Anti HER2 Therapy Related Cardiotoxicity

4:40 PM - 5:00 PM

Panel Discussion

5:00 PM

Closing Remarks

Jayant Raikhelkar, MD

Speakers

Nir Uriel, MD, MSc - Course Director

Jayant Raikhelkar, MD - Course Director

No records found.